Compositions and methods for treating cancer

Abstract

K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.

Description

RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Patent Application Nos. 61 / 622,507, filed Apr. 10, 2012; 61 / 728,145, filed Nov. 19, 2012; and 61 / 794,956, filed Mar. 15, 2013, which are all incorporated herein by reference in their entirety and for all purposes.REFERENCE TO A “SEQUENCE LISTING,” A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED AS AN ASCII TEXT FILE[0002]The Sequence Listing written in file 84850-869921_ST25.TXT, created on Apr. 9, 2013, 28,573 bytes, machine format IBM-PC, MS-Windows operating system, is hereby incorporated by reference.BACKGROUND OF THE INVENTION[0003]K-Ras is the most frequently mutated oncogene in human cancer. However, past attempts to directly target this enzyme with reversible inhibitors have been almost entirely unsuccessful.[0004]Ras proteins are small guanine nucleotide-binding proteins that act as molecular switches by cycling between active GTP-bound and inactive GDP-bound conformations. Ras signa...

AI Technical Summary

Benefits of technology

The patent describes a new method for targeting a protein called K-Ras, which is associated with many types of cancer. The method involves using a small molecule that specifically targets K-Ras and does not bind to a related protein called K-RasG12C. The small molecule can also be used to treat cancer by inhibiting the activity of K-Ras. The patent also describes a new compound that can be used to target K-Ras, and a method for identifying new compounds that can target K-Ras. Overall, the patent provides new tools for targeting K-Ras and developing new treatments for cancer.

Problems solved by technology

However, past attempts to directly target this enzyme with reversible inhibitors have been almost entirely unsuccessful.

Images